The advertisement is misleading because it mischaracterizes the nature of osteoporosis, resulting in an overstatement of Evista's benefits. However, while osteoporosis increases the risk of fracture, not every osteoporotic patient will suffer a fracture. In addition, those who do will not necessarily suffer any loss of independence because many osteoporotic fractures are asymptomatic. Furthermore, while Evista may reduce the risk of fracture, it does not eliminate it altogether. Therefore, these claims misleadingly imply outcomes and guarantees of efficacy for Evista that have not been demonstrated by substantial evidence.
Vertebral fractures are the most common type of osteoporotic fractures in postmenopausal women.
Yet, most vertebral fractures are not symptomatic and do not interfere with a patient's independence. It does not include any evidence that Evista decreases the incidence of hip or wrist fractures. Therefore, this presentation misleadingly suggests that Evista provides greater efficacy than demonstrated by substantial evidence. The advertisement is misleading because it implies that Evista is useful for a broader population than that for which it is indicated. However, menopause alone does not cause osteoporosis and only those with risk factors are candidates for Evista therapy.